Drug-associated nephrotic syndrome in a child with Wilson's disease

Abstract

BACKGROUND: Wilson's disease (WD) (synonyms: Wilson–Konovalov disease, hepatolenticular degeneration, hepatocerebral dystrophy) is a rare, severe, hereditary multisystem disorder that manifests itself primarily in liver, neurological, and psychiatric disorders due to excessive copper deposition in organs and tissues. The long latent course and polymorphism of clinical symptoms make diagnostics difficult. WD manifests itself in childhood, adolescence, and later in life. WD diagnostics is based on a combination of clinical symptoms, laboratory test data (determination of ceruloplasmin levels in the blood, copper excretion in the urine), and molecular genetic testing.

Complex treatment of WD primarily involves adherence to a copper-eliminating diet. A mandatory condition for the effectiveness of treatment of patients with WD is lifelong chelation therapy. The drug of choice in all age groups is penicillamine (a penicillin derivative), which has a significant number of side effects. Adverse reactions against the background of penicillamine therapy develop in about 30% of cases. These include changes in the nervous system (loss of taste, pyridoxine-deficiency polyneuritis), respiratory system (interstitial pneumonitis, diffuse fibrosing alveolitis, Goodpasture's syndrome), digestive system (decreased appetite, nausea, vomiting, diarrhea, aphthous stomatitis, glossitis, intrahepatic cholestasis, pancreatitis), kidneys (nephritis, nephrotic syndrome, hematuria).

CLINICAL CASE DESCRIPTION: The case history of a 6-year-old girl with WD is analyzed. The peculiarity of the clinical case presented by us is the latent course of the disease, which was suspected when cytolysis syndrome was detected in connection with an examination for episodic abdominal pain. Further examination showed a decrease in the concentration of ceruloplasmin, initially borderline values of copper excretion in urine, and questionable values in the penicillamine test. Molecular genetic testing was important for establishing the diagnosis, and confirming the diagnosis. Prescribed chelation therapy with penicillamine led to the normalization of cytolysis syndrome parameters, but caused serious adverse events in the form of nephrotic syndrome, which required replacing penicillamine with trientine and prescribing glucocorticoids. Against the background of treatment correction, stable clinical and laboratory remission of nephrotic syndrome was achieved with satisfactory renal and liver function parameters and no manifestations of cytolysis.

CONCLUSION: A moderate increase in biochemical markers of cytolysis, cholestasis, and bilirubin concentration, refractory to standard treatment, requires in-depth examination, including molecular genetics, to exclude WD. If side effects of penicillamine derivatives are detected, immediate correction of pathogenetic therapy with replacement of the chelating drug is necessary.

Keywords

Wilson's disease / clinical case / children / chelation therapy / penicillamine / adverse drug reaction / nephrotic syndrome

References

[1] https://www.orpha.net/ [Internet]. Wilson disease [cited: 10.09.2024]. Available from: https://www.orpha.net/en/disease/detail/905?name=Wilson&mode=name

[2] Clinical guidelines "Copper metabolism disorders (Wilson's disease)" [Interenet]. [cited: 08.09.2024]. Available from: https://cr.minzdrav.gov.ru/recomend/376_2 (In Russ.)

[3] Krasilnikova EYu, Sokolov AA. Аnalysis of situation in the sphere of health care and drug supply of patients, suffering from rare diseases in the period 2013–2015. Problemy standartizatsii v zdravookhranenii. 2016;(3-4):42–51. EDN: VVWKLT

[4] Guindi M. Wilson disease. Semin Diagn Pathol. 2019;36(6):415–422. doi: 10.1053/j.semdp.2019.07.008

[5] Strokova OA, Gerasimenko IV, Zvereva SI, et al. Wilson–Konovalov disease: epidemiology, diagnostics, treatment. Dnevnik kazanskoy meditsinskoy shkoly. 2021;(3):15–20. EDN: NBVUCB

[6] Mejias SG, Ramphul K. Penicillamine. Treasure Island (FL): StatPearls Publishing; 2024 [Internet]. [cited: 15.09.2024]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK513316/

[7] Wang Y, Fang J, Li B, et al. Clinical and genetic characterization of pediatric patients with Wilson's disease from Yunnan province where ethnic minorities gather. Front Genet. 2023;14:1142968. doi: 10.3389/fgene.2023.1142968

[8] Nayagam JS, Jeyaraj R, Foskett P, et al. ATP7B genotype and chronic liver disease treatment outcomes in Wilson disease: worse survival with loss-of-function variants. Clin Gastroenterol Hepatol. 2023;21(5):1323–1329.e4. doi: 10.1016/j.cgh.2022.08.041

[9] Ryzhkova OP, Kardymon OL, Prohorchuk EB, et al. Guidelines for the interpretation of massive parallel sequencing variants (update 2018, v2). Medical genetics. 2019;18(2):3–24. doi: 10.25557/2073-7998.2019.02.3-24 EDN: JZLJUE

[10] Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2017;19(5):606. doi: 10.1038/gim.2017.18 Erratum in: Genet Med. 2013;15(7):565–574. doi: 10.1038/gim.2013.73

[11] Fellers FX, Shahidi NT. The nephrotic syndrome induced by penicillamine therapy. Am J Dis Child. 1959;98:669.

[12] Siafakas CG, Jonas MM, Alexander S, et al. Early onset of nephrotic syndrome after treatment with D-penicillamine in a patient with Wilson's disease. Am J Gastroenterol. 1998;93(12):2544–2546. doi: 10.1111/j.1572-0241.1998.00715.x

[13] Kang S, Cho MH, Hyun H, et al. A pediatric case of a D-penicillamine induced ANCA-associated vasculitis manifesting a pulmonary-renal syndrome. J Korean Med Sci. 2019;34(24):e173. doi: 10.3346/jkms.2019.34.e173

[14] Davison AM, Day AT, Golding JR, Thomson D. Effect of penicillamine on the kidney. Proc R Soc Med. 1977;70 (Suppl. 3):109–113.

[15] Athanasopoulou D, Lionaki S, Skalioti C, et al. Drug-induced podocytopathies: report of four cases and review of the literature. Life (Basel). 2023;13(6):1264. doi: 10.3390/life13061264

[16] Dang J, Chevalier K, Letavernier E, et al. Kidney involvement in Wilson's disease: a review of the literature. Clin Kidney J. 2024;17(4):sfae058. doi: 10.1093/ckj/sfae058

[17] Lee EJ, Woo MH, Moon JS, Ko JS. Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients. Orphanet J Rare Dis. 2024;19(1):261. doi: 10.1186/s13023-024-03271-1

RIGHTS & PERMISSIONS

Eco-Vector